Unknown PHASE1 INTERVENTIONAL 4-arm NCT03731390

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

A Phase I Clinical Study for Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Repeated Doses, Dose Escalation of GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Sponsor: Chinese Academy of Medical Sciences

Conditions Lymphoma Tumor, Solid

Interventions GR1405 injection

Updated 7 times since 2018 Last updated: Nov 4, 2018 Started: Nov 30, 2018 Primary completion: Oct 31, 2019 Completion: Oct 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03731390, this PHASE1 trial focuses on Lymphoma and Tumor, Solid and remains ongoing. Sponsored by Chinese Academy of Medical Sciences, it has been updated 7 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE1
Dec 2022 — Oct 2023 [monthly]

Unknown Status PHASE1
Nov 2021 — Dec 2022 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE1
Dec 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Medical Sciences

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China